Profile of Prof. Dr. Markus Pfirrmann

Lead of RG Clinical Trials and Prognosis Research; Acting Deputy Director of the Department of Medical Biometry and of the IBE

Brief CV

1987–1993: Studied statistics at Ludwig Maximilian University in Munich

1993–1994: Master of Science in “Applied Stochastic Systems” at University College London

1995–1997: Research associate at the IBE, leading the international “Collaborative Prognostic Factors Project” to predict survival in patients with chronic myeloid leukemia (CML) undergoing treatment with interferon-alpha.

1997–1998: Project manager and lead biometrician for several clinical trials on CML at the BZT Biometric Center for Therapeutic Studies, Munich

1998–2007 Project manager and lead biometrician for several clinical trials on chronic myeloid leukemia (CML) and acute myeloid leukemia (AML) at the GIS Society for Information Processing and Statistics in Medicine e.V.

In 2000, jointly with co-authors, received the Paul Martini Prize from the German Society for Medical Informatics, Biometrics, and Epidemiology (GMDS e.V.).

Since 2007, Project Manager and Lead Biometrician for several clinical trials on CML and AML at the IBE

2007: Ph.D. thesis on “The Development and Validation of a Prognostic Score for Patients with Chronic Myeloid Leukemia, Incorporating Cytogenetic Remission as a Time-Dependent Covariate”

In 2012, assumed sole responsibility for managing all new clinical trials within the Chair of “Medical Information Processing, Biometrics, and Epidemiology” and, as part of this, introduced the electronic data collection system “Marvin.”

Since 2016, Head of the “Clinical Trials and Prognosis Research” research group.

2016 Habilitation thesis on the topic “The Application of Advanced Statistical Methodology to Clinical Questions—Synergies in Joint Scientific Projects Between Clinicians and Statisticians”

2024 Appointed Adjunct Professor at the IBE

Main Areas of Research

  • Methodology, Planning, and Analysis of Registry Studies and Clinical Trials
  • Prognosis Research
  • Survival Analysis
  • Analysis of Competing Events

Current Studies and Projects

Name of projectDescription
CML V TIGER-StudyA prospective, randomized, open-label, multicenter therapeutic study comparing nilotinib with and without interferon as induction therapy, and nilotinib versus interferon as maintenance therapy for the treatment of chronic myeloid leukemia (CML).
DasaHIT-StudyA prospective, randomized, open-label, multicenter dasatinib dose-optimization study to evaluate the tolerability and efficacy of medication taken on 5 out of 7 days of the week versus daily dosing in patients with CML.
FASCINATION-StudyProspective, non-randomized, open-label, multicenter study of deep molecular response in CML patients treated with a combination of an established tyrosine kinase inhibitor and asciminib.
TRACE-StudyA prospective, randomized, double-blind, placebo-controlled, multicenter study of the efficacy of multi-specific T-cell infusion against chemo-refractory viral infections following allogeneic stem cell transplantation.
NAUT-StudyProspective, open-label, multicenter registry study to investigate the feasibility of discontinuing therapy again in CML patients who relapsed after the first discontinuation of therapy but subsequently achieved deep remission following renewed nilotinib therapy lasting at least two years.
PONTrack-StudyProspective, open-label, multicenter registry study on deep molecular response in CML patients who have received 2 years of ponatinib treatment.
CML-TFR-RegistryA registry for the prospective assessment of treatment-free molecular remission status in CML, with the aim of investigating prognostic factors.
International CML Genomics AllianceGlobal genomic data to evaluate the clinical relevance of pathogenic variants at the time of diagnosis of CML in the chronic phase with regard to events such as the occurrence of BCR::ABL1 kinase domain mutations, disease progression, or death.
ESTIMATION-StudyRegistry for the prospective assessment of molecular remission success in CML patients with the T315I mutation who are being treated with asciminib.
EURO-SKI-StudyRegistry for prognostic research on the maintenance of molecular remission in CML patients following discontinuation of therapy.
ELN/EUTOS-RegistryA registry for prognostic research on prospectively enrolled CML patients treated predominantly with imatinib and their outcomes over the course of therapy.

Other Relevant Activities and Memberships in Working Groups

  • Supervision of master’s and doctoral theses
  • Collaboration with clinical colleagues on additional, individual projects addressing specific methodological questions
  • Methodological reviewer for the journals “Leukemia,” “Journal of Clinical Oncology,” “Lancet Oncology,” “Blood,” and “BMC Medical Research Methodology”
  • Member of the German Society for Medical Informatics, Biometry, and Epidemiology (GMDS)
  • Member of the “Cancer Therapy Studies” Expert Committee at German Cancer Aid
  • Member of the European Investigators on Chronic Myeloid Leukemia
  • Member of the European Leukemia Network (ELN)
  • Member of the “Acute and Chronic Leukemias” Competence Network

Teaching

  • Lecturer at the MeCuM seminars 7M2808 I1 MeCuM Science Intensive Block “Basics!” Fundamentals of Clinical Epidemiology and 7M3007 Seminar: I2 MeCuM Science Intensive Block “Advanced!”
  • Since 2015, annual organization of the workshop on “Understanding Modern Statistical Methods Applied to Clinical Trials in Leukemia” as part of the European LeukemiaNet (ELN) Symposium
  • Scientific consultation for projects at the hospital and for medical doctoral dissertations

List of publications